

# Joan M Sweet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5645990/publications.pdf>

Version: 2024-02-01

78  
papers

3,504  
citations

145106

33  
h-index

156644

58  
g-index

78  
all docs

78  
docs citations

78  
times ranked

4211  
citing authors

#	ARTICLE	IF	CITATIONS
1	Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer. <i>Journal of Robotic Surgery</i> , 2022, 16, 369-375.	1.0	8
2	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. <i>European Urology Open Science</i> , 2022, 40, 46-53.	0.2	6
3	Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. <i>Prostate Cancer</i> , 2022, 2022, 1-8.	0.4	1
4	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , 2021, 4, 483-491.	2.6	39
5	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , 2021, 4, 289-296.	2.6	13
6	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. <i>Clinical Cancer Research</i> , 2021, 27, 2340-2351.	3.2	10
7	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , 2020, 138, 69-76.	0.5	3
8	A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , 2020, 14, 346-351.	0.3	0
9	Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors. <i>Canadian Urological Association Journal</i> , 2020, 14, 411-415.	0.3	6
10	Partial orchiectomy: The Princess Margaret cancer centre experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 605.e19-605.e24.	0.8	15
11	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , 2019, 37, 1919-1926.	0.8	47
12	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. <i>Molecular Metabolism</i> , 2019, 25, 119-130.	3.0	55
13	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 61-66.	0.4	8
14	Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases. <i>Journal of Clinical Pathology</i> , 2019, 72, 363-367.	1.0	5
15	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , 2019, 74, 474-482.	1.6	44
16	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , 2019, 144, 1676-1684.	2.3	57
17	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , 2018, 200, 126-135.	0.2	107
18	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001.	1.6	26

#	ARTICLE	IF	CITATIONS
19	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	21
20	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.2	2
21	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , 2018, 122, 814-822.	1.3	8
22	Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?. <i>Histopathology</i> , 2017, 71, 926-933.	1.6	23
23	Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors. <i>Pathology Research and Practice</i> , 2017, 213, 1412-1418.	1.0	14
24	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017, 71, 120-127.	0.9	54
25	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2017, 12, 59-66.	0.3	12
26	Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5095-TPS5095.	0.8	0
27	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. <i>Canadian Urological Association Journal</i> , 2016, 10, 204.	0.3	10
28	Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma. <i>Clinical Oncology</i> , 2016, 28, 648-654.	0.6	16
29	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 1265-1273.	3.2	23
30	Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT).. <i>Journal of Clinical Oncology</i> , 2016, 34, 493-493.	0.8	1
31	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 194, 386-391.	0.2	23
32	A pilot "window of opportunity" neoadjuvant study of metformin in localised prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 252-258.	2.0	68
33	PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. <i>Modern Pathology</i> , 2013, 26, 435-447.	2.9	73
34	Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. <i>BJU International</i> , 2013, 112, 1088-1095.	1.3	40
35	Canadian consensus guidelines for the management of testicular germ cell cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 19.	0.3	119
36	Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5070-5070.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue. <i>Journal of Clinical Pathology</i> , 2012, 65, 729-734.	1.0	29
38	Utility of serum tumor markers during surveillance for stage I seminoma. <i>Cancer</i> , 2012, 118, 5245-5250.	2.0	33
39	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. <i>BJU International</i> , 2012, 110, 804-811.	1.3	96
40	A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens. <i>Canadian Urological Association Journal</i> , 2012, 6, E27-31.	0.3	20
41	A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15118-e15118.	0.8	0
42	Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models. <i>International Urology and Nephrology</i> , 2011, 43, 23-30.	0.6	14
43	mTOR-RAPTOR and 14-3-3 $\hat{A}$ immunohistochemical expression in high grade prostatic intraepithelial neoplasia and prostatic adenocarcinomas: a tissue microarray study. <i>Journal of Clinical Pathology</i> , 2011, 64, 683-688.	1.0	15
44	Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): A tissue microarray study (TMA). <i>Prostate</i> , 2010, 70, 1429-1436.	1.2	16
45	MRI and contrast-enhanced ultrasound monitoring of prostate microwave focal thermal therapy: An in vivo canine study. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 136-143.	1.9	38
46	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer After External-Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 425-430.	0.4	234
47	Prognostic Significance of $\hat{I}\pm$ -Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies. <i>Journal of Urology</i> , 2008, 179, 1751-1755.	0.2	15
48	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. <i>Radiotherapy and Oncology</i> , 2008, 88, 53-60.	0.3	30
49	Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1503-1512.	2.1	123
50	Eyelid metastasis from mediastinal teratoma with malignant transformation. <i>Acta Oncologica</i> , 2007, 46, 1200-1201.	0.8	4
51	Transcriptional Activity of Androgen Receptor Is Modulated by Two RNA Splicing Factors, PSF and p54nrb. <i>Molecular and Cellular Biology</i> , 2007, 27, 4863-4875.	1.1	91
52	The Continuing Importance of Transrectal Ultrasound Identification of Prostatic Lesions. <i>Journal of Urology</i> , 2007, 177, 516-520.	0.2	68
53	Making Sense of Prostate Specific Antigen: Improving its Predictive Value in Patients Undergoing Prostate Biopsy. <i>Journal of Urology</i> , 2006, 175, 489-494.	0.2	14
54	Prostate Cancers Scored as Gleason 6 on Prostate Biopsy are Frequently Gleason 7 Tumors at Radical Prostatectomy: Implication on Outcome. <i>Journal of Urology</i> , 2006, 176, 979-984.	0.2	132

#	ARTICLE	IF	CITATIONS
55	Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy. <i>Clinical Cancer Research</i> , 2006, 12, 6452-6458.	3.2	38
56	Comparison of annexin II, p63 and Â-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. <i>Journal of Clinical Pathology</i> , 2006, 60, 773-780.	1.0	26
57	The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy. <i>Clinical Cancer Research</i> , 2005, 11, 8391-8397.	3.2	52
58	A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy. <i>Radiotherapy and Oncology</i> , 2005, 76, 11-17.	0.3	47
59	Recurrence of anti-GBM disease 8 years after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 491-494.	0.4	35
60	Variation in patterns of practice in diagnosing screen-detected prostate cancer. <i>BJU International</i> , 2004, 94, 1239-1244.	1.3	13
61	Spermatocytic Seminoma: A Review. <i>European Urology</i> , 2004, 45, 495-498.	0.9	66
62	Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 750-757.	0.4	129
63	A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. <i>Cancer Gene Therapy</i> , 2003, 10, 755-763.	2.2	61
64	Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. <i>Oncogene</i> , 2003, 22, 1978-1987.	2.6	76
65	Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection. <i>Journal of Clinical Oncology</i> , 2003, 21, 2312-2319.	0.8	36
66	The Uncertainty Of Radio Frequency Treatment Of Renal Cell Carcinoma: Findings At Immediate And Delayed Nephrectomy. <i>Journal of Urology</i> , 2002, 167, 1587-1592.	0.2	214
67	The Uncertainty Of Radio Frequency Treatment Of Renal Cell Carcinoma: Findings At Immediate And Delayed Nephrectomy. <i>Journal of Urology</i> , 2002, , 1587-1592.	0.2	33
68	V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. <i>Urology</i> , 2001, 57, 199-204.	0.5	83
69	DEVELOPMENT OF A RADIOFREQUENCY BASED THERMAL THERAPY TECHNIQUE IN AN IN VIVO PORCINE MODEL FOR THE TREATMENT OF SMALL RENAL MASSES. <i>Journal of Urology</i> , 2001, 166, 292-298.	0.2	84
70	Evidence of Chromosomal Instability in Prostate Cancer Determined by Spectral Karyotyping (SKY) and Interphase FISH Analysis. <i>Neoplasia</i> , 2001, 3, 62-69.	2.3	49
71	First recurrence of focal segmental glomerulosclerosis in a third renal allograft. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 407-409.	0.4	4
72	SIGNIFICANCE OF THE CAG REPEAT POLYMORPHISM OF THE ANDROGEN RECEPTOR GENE IN PROSTATE CANCER PROGRESSION. <i>Journal of Urology</i> , 2000, 164, 567-572.	0.2	75

#	ARTICLE	IF	CITATIONS
73	A COMPARATIVE ANALYSIS OF SEXTANT AND AN EXTENDED 11-CORE MULTISITE DIRECTED BIOPSY STRATEGY. Journal of Urology, 2000, 163, 152-157.	0.2	396
74	Ancrod improves survival in murine systemic lupus erythematosus. Kidney International, 1990, 37, 29-35.	2.6	14
75	Myeloma-Like Cast Nephropathy Associated with Acinar Cell Carcinoma of the Pancreas. American Journal of Nephrology, 1988, 8, 421-424.	1.4	7
76	Granulomatous Interstitial Nephritis Associated With Allopurinol Therapy. Journal of Urology, 1987, 137, 171-171.	0.2	0
77	Expression of macrophage procoagulant activity in murine systemic lupus erythematosus.. Journal of Clinical Investigation, 1986, 78, 887-893.	3.9	18
78	Amyloidosis and systemic lupus erythematosus. Human Pathology, 1981, 12, 853-856.	1.1	19